Noah Goodman's most recent trade in Kymera Therapeutics Inc was a trade of 5,000 Common Stock done at an average price of $21.1 . Disclosure was reported to the exchange on June 25, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Kymera Therapeutics Inc | Noah Goodman | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 21.05 per share. | 25 Jun 2026 | 5,000 | 55,195 | - | 21.1 | 105,250 | Common Stock |
| Kymera Therapeutics Inc | Noah Goodman | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Jun 2026 | 5,000 | 90,000 | - | - | Stock Option (Right to Buy) | |
| Kymera Therapeutics Inc | Noah Goodman | Chief Business Officer | Sale of securities on an exchange or to another person at price $ 119.00 per share. | 25 Jun 2026 | 2,500 | 50,195 | - | 119 | 297,500 | Common Stock |
| Kymera Therapeutics Inc | Noah Goodman | Chief Business Officer | Sale of securities on an exchange or to another person at price $ 109.00 per share. | 25 Jun 2026 | 2,500 | 52,695 | - | 109 | 272,500 | Common Stock |
| Kymera Therapeutics Inc | Noah Goodman | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 21.05 per share. | 22 Jun 2026 | 2,500 | 52,695 | - | 21.1 | 52,625 | Common Stock |
| Kymera Therapeutics Inc | Noah Goodman | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Jun 2026 | 2,500 | 95,000 | - | - | Stock Option (Right to Buy) | |
| Kymera Therapeutics Inc | Noah Goodman | Chief Business Officer | Sale of securities on an exchange or to another person at price $ 99.00 per share. | 22 Jun 2026 | 2,500 | 50,195 | - | 99 | 247,500 | Common Stock |
| Kymera Therapeutics Inc | Noah Goodman | Chief Business Officer | Sale of securities on an exchange or to another person at price $ 90.00 per share. | 14 Apr 2026 | 1,347 | 50,195 | - | 90 | 121,230 | Common Stock |
| Kymera Therapeutics Inc | Noah Goodman | Chief Business Officer | Sale of securities on an exchange or to another person at price $ 86.62 per share. | 09 Apr 2026 | 3,094 | 58,712 | - | 86.6 | 267,996 | Common Stock |
| Kymera Therapeutics Inc | Noah Goodman | Chief Business Officer | Sale of securities on an exchange or to another person at price $ 87.11 per share. | 09 Apr 2026 | 2,670 | 56,042 | - | 87.1 | 232,586 | Common Stock |
| Kymera Therapeutics Inc | Noah Goodman | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Apr 2026 | 2,500 | 97,500 | - | - | Stock Option (Right to Buy) | |
| Kymera Therapeutics Inc | Noah Goodman | Chief Business Officer | Sale of securities on an exchange or to another person at price $ 89.00 per share. | 09 Apr 2026 | 2,500 | 53,542 | - | 89 | 222,500 | Common Stock |
| Kymera Therapeutics Inc | Noah Goodman | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 21.05 per share. | 09 Apr 2026 | 2,500 | 61,806 | - | 21.1 | 52,625 | Common Stock |
| Kymera Therapeutics Inc | Noah Goodman | Chief Business Officer | Sale of securities on an exchange or to another person at price $ 87.35 per share. | 09 Apr 2026 | 2,000 | 51,542 | - | 87.4 | 174,700 | Common Stock |
| Kymera Therapeutics Inc | Noah Goodman | Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Mar 2026 | 18,450 | 18,450 | - | - | Stock Option (Right to Buy) | |
| Kymera Therapeutics Inc | Noah Goodman | Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Mar 2026 | 9,225 | 59,306 | - | 0 | Common Stock | |
| Kymera Therapeutics Inc | Noah Goodman | Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Apr 2025 | 100,000 | 100,000 | - | - | Stock Option (Right to Buy) | |
| Kymera Therapeutics Inc | Noah Goodman | Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Apr 2025 | 50,000 | 50,081 | - | 0 | Common Stock |